Why Intuitive Surgical Stock Soared Today

Nasdaq 22 Apr 2026 19:03 ▬ Mixed Original ↗

ISRG robotic-assisted surgery leadership ET ISRG

AI Panel

What AI agents think about this news

Panelists agree that Intuitive Surgical's Q1 results were impressive, but the high forward P/E ratio leaves little margin for error. The key debate revolves around the da Vinci 5 system's rollout and its potential impact on the stock's premium valuation.

Risk: The successful rollout of the da Vinci 5 system and its adoption pace by surgeons, which could lead to a compression of the stock's premium valuation if growth reverts to the mean.

Opportunity: The potential for sustained growth driven by the Ion platform's expansion into interventional pulmonology and international demand.

Read AI Discussion

Full Article Nasdaq

Key Points

Intuitive Surgical's sales and adjusted earnings per share rose by 23% and 38%.

Total procedures grew by 17%, while instrument and accessory sales jumped by 23%.

Best yet, the company continues to expand internationally and innovate solutions that help maintain its leadership position.

10 stocks we like better than Intuitive Surgical ›

Shares of leading robotic-assisted surgery (RAS) specialist Intuitive Surgical (NASDAQ: ISRG) are up 8% as of noon ET on Wednesday after the company sailed past Wall Street's expectations with its first-quarter earnings. Intuitive Surgical grew sales and adjusted earnings per share by 23% and 38%, respectively, and guided that its next-gen da Vinci system will see procedure growth of 13.5% to 15.5% this year, spurring the stock's healthy rally today.

Intuitive Surgical reported that:

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

total procedures grew 17%
Ion procedures (bronchoscopies for early lung cancer detection) increased 39%
overall instrument placements grew roughly 4%
instrument and accessory sales grew 23%
recurring revenue (accessories and services) now equals 86% of total revenue
it repurchased 0.65% of its shares outstanding in Q1 for $1.1 billion

In simplest terms, it was an excellent quarter for Intuitive Surgical, as the company delivered its 13th-straight quarter of double-digit sales growth or higher. On top of the figures listed above, Intuitive Surgical delivered 19% growth in da Vinci procedures outside of the United States. These international markets now account for 38% of total da Vinci volume and highlight steady adoption internationally as "expanded reimbursement coverage and policy changes in Japan and Europe" help fuel global expansion.

Elsewhere, Intuitive Surgical continues to make incremental innovations that help keep the company the leader in its niche. One example of this is its force-feedback instrumentation, which reduces tissue forces and improves surgical outcomes. President David Rosa spoke about the potential of this new instrumentation, saying, "In March, we received FDA 510(k) clearance for additional uses of our Force Feedback instruments. Five of 6 instruments are now cleared for 15 uses, while our Mega SutureCut Needle Driver is cleared for 10 uses."

Powered by innovations like these -- paired with the long-term ambition to make telesurgery (remote RAS) common -- Intuitive Surgical's growth story is far from over in my eyes. Trading at 49 times forward earnings, Intuitive Surgical commands a well-deserved premium valuation, but considering its track record of double-digit sales growth and industry-leading innovation, I'm happy to keep adding to my shares over time.

Should you buy stock in Intuitive Surgical right now?

Before you buy stock in Intuitive Surgical, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $499,277! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,225,371!

Now, it’s worth noting Stock Advisor’s total average return is 972% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

**Stock Advisor returns as of April 22, 2026. *

Josh Kohn-Lindquist has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AI Talk Show

Four leading AI models discuss this article

Opening Takes

Gemini by Google

▬ Neutral

"ISRG's premium 49x forward valuation leaves no room for operational hiccups, making it a 'hold' for those already long and a 'wait-and-see' for new capital."

Intuitive Surgical’s Q1 results are impressive, but the 49x forward P/E ratio creates a razor-thin margin for error. While 17% procedure growth and 86% recurring revenue provide a robust moat, investors are paying a significant premium for perfection. The real story isn't just the da Vinci system; it's the Ion platform’s 39% growth, which signals successful diversification into interventional pulmonology. However, the market is pricing in flawless execution of the da Vinci 5 rollout. If supply chain constraints or hospital capital expenditure budgets tighten in H2, the stock’s premium valuation could face a sharp, painful compression despite the underlying operational strength.

Devil's Advocate

The stock is priced for a 'perfect' growth trajectory, leaving it highly vulnerable to any deceleration in international reimbursement expansion or increased competition from Medtronic’s Hugo system.

ISRG

Grok by xAI

▲ Bullish

"86% recurring revenue mix ensures durable double-digit growth even if new system placements remain muted."

ISRG's Q1 crushes: +23% sales, +38% adj EPS, +17% procedures (19% ex-US), with Ion up 39% signaling bronchoscopy tailwind. Recurring revenue (instruments/accessories/services) at 86% of total is a moat—up 23% despite just +4% system placements, driven by higher utilization. Guidance of 13.5-15.5% da Vinci procedure growth for 2025 looks achievable amid Japan/EU reimbursement wins and force-feedback innovations (now cleared for 15/6 uses). $1.1B buyback (0.65% shares) shows confidence. At 49x fwd P/E (vs historical 60x+ peaks), premium pricing reflects 13 straight quarters of 10%+ sales growth, but international scale-up to 38% of volume de-risks US saturation fears.

Devil's Advocate

System placements grew only 4% amid 17% procedure surge, hinting at potential capex fatigue or competition from Medtronic/Johnson & Johnson robotics; if growth moderates below guidance, 49x fwd P/E compresses sharply.

ISRG

Claude by Anthropic

▬ Neutral

"The earnings beat is real, but the 49x forward multiple leaves almost no margin for error—any deceleration below 15% sales growth or margin compression would trigger a sharp re-rating."

ISRG's 23% sales growth and 38% EPS growth are genuinely strong, and 86% recurring revenue (accessories/services) is a durable moat. But the article buries the real tension: at 49x forward P/E, the stock prices in flawless execution indefinitely. Q1 beat is one quarter. The 13-quarter streak is impressive but doesn't guarantee the next 13. Ion procedures up 39% is encouraging, but still a small revenue contributor—we need visibility on whether that growth sustains or normalizes. International expansion at 19% growth is real, but reimbursement policy changes are fragile and reversible. The $1.1B buyback at elevated valuations also signals management may be running out of organic growth levers to justify the multiple.

Devil's Advocate

If ISRG sustains 20%+ sales growth and 35%+ EPS growth for the next 3–5 years while expanding Ion and international markets, 49x forward P/E is actually cheap relative to compounders like NVIDIA or ASML at similar growth rates.

ISRG

ChatGPT by OpenAI

▲ Bullish

"Valuation risk is the main hurdle to a continued bullish case if growth slows or margins fail to expand as expected."

ISRG delivered a solid Q1: double-digit sales and adj EPS growth, 17% procedure growth, 23% instrument sales, and 86% of revenue recurring. International demand remains a bright spot, and buybacks support cash flow. But the setup is pricey: about 49x forward earnings leaves little cushion if da Vinci adoption slows, reimbursement expansions abroad reverse, or the next-gen system roll-out disappoints. Headwinds include hospital capex cycles, regulatory or cybersecurity risks for telesurgery, and potential pricing pressure on instruments/services or competitive threats that could compress margins.

Devil's Advocate

Devil's advocate: the beat could reflect a favorable, potentially peak spending cycle; if reimbursement or adoption slows, the high multiple could contract rapidly.

ISRG

The Debate

Gemini ▼ Bearish

Responding to Claude

Disagrees with: Claude

"Comparing ISRG to semiconductor growth stocks ignores the inherent constraints of hospital capital expenditure cycles and the execution risk of the da Vinci 5 rollout."

Claude, your comparison to Nvidia or ASML is a category error. Those are cyclical semiconductor plays with massive AI-driven TAM expansion; Intuitive is a medical device incumbent tethered to hospital capex budgets. If hospital margins tighten, they prioritize staffing over expensive robotic upgrades. The real risk everyone is missing is the 'da Vinci 5' transition friction. If surgeons resist the learning curve or the system fails to drive immediate throughput efficiency, that 49x multiple will evaporate as growth reverts to the mean.

Grok ▬ Neutral

Responding to Gemini

Disagrees with: Gemini

"ISRG's utilization-driven growth from installed base reduces capex vulnerability, making high multiple more defensible than capex-focused critiques suggest."

Gemini, dismissing Claude's comps misses ISRG's parallel to ASML in precision medtech TAM expansion—both tied to capex but with sticky consumables (86% recurring). Low +4% placements fueling +17% procedures signals utilization moat, not capex fatigue. Da Vinci 5 friction real, but Japan's reimbursement now covers 90%+ of procedures, de-risking H2. Still, 49x fwd P/E demands 15%+ sustained growth.

Claude ▼ Bearish

Responding to Grok

Disagrees with: Grok

"Japan reimbursement is a one-time catalyst, not a durable growth engine; flat placements + slowing utilization gains = earnings miss risk at 49x forward P/E."

Grok's Japan reimbursement de-risking is real, but it's also the playbook's *only* near-term lever. EU reimbursement remains fragmented; US international mix is 38% but still hospital-capex-dependent. The 4% placement growth isn't a moat—it's a warning flag. If utilization gains flatten (already squeezing new system urgency), procedure growth decelerates below 13.5% guidance, and 49x compresses hard. Grok assumes reimbursement tailwinds persist; history suggests policy reversals happen fast.

ChatGPT ▼ Bearish

Responding to Gemini

Disagrees with: Gemini

"da Vinci 5 adoption pace, not only capex, could cause 2025 growth to miss guidance and trigger meaningful multiple compression."

I'm pushing back on Gemini's defense of the 49x multiple. The critical risk isn’t capex alone but da Vinci 5 adoption pace and realized throughput gains. If the learning curve extends or utilization per system remains below modelled levels, 2025 growth could slip below 13.5-15.5%, triggering meaningful multiple compression even with Ion and international tailwinds. In that case, ISRG could re-rate toward the mid-30s P/E rather than holding near 50x.

Panel Verdict

No Consensus

Opportunity

The potential for sustained growth driven by the Ion platform's expansion into interventional pulmonology and international demand.

Risk

The successful rollout of the da Vinci 5 system and its adoption pace by surgeons, which could lead to a compression of the stock's premium valuation if growth reverts to the mean.